Overview

  • Product nameAnti-EGR2 antibody
    See all EGR2 primary antibodies
  • Description
    Rabbit polyclonal to EGR2
  • Tested applicationsSuitable for: WB, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse
    Predicted to work with: Rat, Human
  • Immunogen

    Synthetic peptide derived from the N terminal domain of Mouse EGR2.

Properties

Applications

Our Abpromise guarantee covers the use of ab90518 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/2000. Predicted molecular weight: 50 kDa.
IHC-Fr Use at an assay dependent concentration.

Target

  • FunctionSequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4.
  • Involvement in diseaseDefects in EGR2 are a cause of congenital hypomyelination neuropathy (CHN) [MIM:605253]. Inheritance can be autosomal dominant or recessive. Recessive CHN is also known as Charcot-Marie-Tooth disease type 4E (CMT4E). CHN is characterized clinically by early onset of hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities.
    Defects in EGR2 are a cause of Charcot-Marie-Tooth disease type 1D (CMT1D) [MIM:607678]. CMT1D is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.
    Defects in EGR2 are a cause of Dejerine-Sottas syndrome (DSS) [MIM:145900]; also known as Dejerine-Sottas neuropathy (DSN) or hereditary motor and sensory neuropathy III (HMSN3). DSS is a severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. DSS is characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome.
  • Sequence similaritiesBelongs to the EGR C2H2-type zinc-finger protein family.
    Contains 3 C2H2-type zinc fingers.
  • Post-translational
    modifications
    Ubiquitinated by WWP2 leading to proteasomal degradation.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AT591 antibody
    • CMT1D antibody
    • CMT4E antibody
    • DKFZp686J1957 antibody
    • E3 SUMO-protein ligase EGR2 antibody
    • Early growth response 2 antibody
    • Early growth response protein 2 antibody
    • EGR-2 antibody
    • egr2 antibody
    • EGR2_HUMAN antibody
    • FLJ14547 antibody
    • KROX 20 Drosophila homolog antibody
    • Krox 20 homolog Drosophila antibody
    • KROX-20, Drosophila, homolog (early growth response-2) antibody
    • KROX20 antibody
    • Krox20 protein antibody
    • Zinc finger protein Krox-20 antibody
    see all

References for Anti-EGR2 antibody (ab90518)

ab90518 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab90518.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"